Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia

Table 2

Initial characteristics and clinical outcomes of 27 pediatric patients with AML.

Number of patients	27
Age, median (yr), range	5.9 (0.05–16.5)
Sex
Male	11 (40.74)
Female	16 (59.26)
Total blood counts
Leucocytes, median (range)/uL	23,000 (3,100–254,000)
Platelets, median (range)/uL	36,000 (3,000–152,000)
Hemoglobin, median (range) g/dL	6.8 (2.8–13.0)
WBC, >100,000/uL, (%)	8 (29.6)
CNS positive, (%)	2 (7.4)
FAB, (%)
M1	9 (33.3)
M2	7 (25.9)
M4	8 (29.6)
M5	1 (3.7)
M6	2 (7.4)
M7	0
Remission
After the first induction course (%)	20 (74.1)
After the second induction course (%)	1 (3.7)
Nonresponders (%)	3 (11.1)
Not assessed	3 (11.1)
Relapses (%)	5 (18.5)
Deaths (%)	13 (48.1)
Early deaths	(38.4)
Treatment-related	8 (61.5)
Leukemia-related	5 (38.5)